Navigation Links
UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
Date:1/28/2010

OAK RIDGE, Tenn., Jan. 28, 2010 -- In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of the Department of Energy laboratory.

The protein therapy treatment under development takes advantage of the Nell-1 gene's cell-signaling pathway that controls tissue growth and maturation in mammalian organs.

The foundation for this therapy is research performed by Cymbeline Culiat, who as an ORNL systems genetics researcher identified the role that the Nell-1 pathway plays in tissue growth and maturation.

Today, Culiat is leading the NellOne research effort to translate the Nell-1 pathway discoveries into a therapy that restores both mass and function to damaged human tissues, such as heart and skeletal muscle.

If successful, the protein therapy could improve the lives of victims of heart attacks and severe muscle wounds. Other therapies, such as stem-cell treatments, have succeeded in triggering tissue formation but fall short in restoring the actual function of the tissue.

Battelle Ventures, with its Knoxville-based affiliate fund, Innovation Valley Partners (IVP), created NellOne with a $1.5-million seed investment in 2008.

"Our executing this license is confirmation from NellOne that sufficient proof-of-principle experiments have been completed and that the company is progressing toward the commercialization of an extremely promising technology that could one day vastly improve the lives of countless heart patients," said Tracy Warren, NellOne chief executive officer and Battelle Ventures general partner.

"NellOne is currently dedicated to the development of intellectual property and moving into a clinical setting," Warren continued, noting that it operates out of the IVP office in Knoxville. "A
'/>"/>

Contact: Bill Cabage
cabagewh@ornl.gov
865-574-4399
DOE/Oak Ridge National Laboratory
Source:Eurekalert

Page: 1 2

Related biology news :

1. Virginia Tech licenses GenoCAD source code to ISCB
2. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
3. MSU licenses plant oil enhancement technology to BASF Plant Science
4. UGA licenses technology to make fuel from dead forests and agricultural waste
5. UGA licenses new Bermuda grass that thrives in sun and shade
6. UGA licenses invention that kills food-borne pathogens in minutes
7. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
8. Syntermed licenses Emory ERTb software for enhanced cardiac imaging
9. $3.75 million grant advances tissue engineering partnership
10. New pathway discovered that may prevent tissue damage resulting from inflammation
11. Supportive materials will help regenerate heart tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... German . , Together with colleagues from ... for Allergy and Environment of the Technische Universitt Mnchen, ... major gene for allergic diseases. The gene was localized ... genome at the Helmholtz Zentrum Mnchen. The newly discovered ...
... of St. Andrews, United Kingdom, have helped determine why relearning ... cause a recollection of other associated, previously learned information. ... the learned information is forgotten. Details are published August ... When one learns a language and then doesn,t use ...
... 2008)-- U.S. Energy Secretary Samuel Bodman and Enrique Santacana, ... keynote speakers during GridWeek 2008 in Washington. ... and International Trade Center, is an annual gathering of ... major partner of GridWeek 2008. Bodman and ...
Cached Biology News:Munich researchers discover key allergy gene 2Energy secretary, IEEE-member industry leader to deliver keynote addresses during GridWeek 2008 2
(Date:4/17/2015)... 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; ... that develops and commercializes proprietary technologies and products ... it has received approval from the TSX Venture ... common share purchase warrants ("the Warrants") of the ... Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Global ... the GTCbio Stem Cell Summit 2015 April 27 - ... the latest developments in all areas of stem cell ... of stem cells and regenerative medicine. , The ... trials, as well as translational research in stem cell ...
(Date:4/16/2015)... Bythewood, South Carolina (PRWEB) April 17, 2015 ... solutions and steam system services, released their newly ... 2015. The customer facing website effectively promotes ... proposition. , All the information that a ... training, steam system services, company capabilities, industries serviced, ...
(Date:4/16/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... results on Thursday, April 30, 2015 at 4:00 PM ... host a conference call at 4:30 PM Eastern Time ... outlook for the future. , The conference call will ... homepage and in the Investor Relations section of Cytokinetics’ ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") ... in a Phase 1b clinical trial of PX-12 ... proprietary small molecule,inhibitor of thioredoxin, a protein that ... survival and drug resistance of,many cancers., The ...
... and present a poster on proprietary siRNA ... targeting and ... Pharmaceuticals, Inc., a,development-stage pharmaceutical company discovering and developing novel,RNA ... Cambridge Healthcare Institute,s 9th Annual Beyond,Genome Conference on June ...
... Calif., June 10 DURECT Corporation,(Nasdaq: DRRX ... (NDA) for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to ... investigational drug, is a long,acting oral formulation of ... on DURECT,s ORADUR technology, Remoxy is designed to ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 2Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... Many modifications of Eagle's ... the original formulation. The most ... Modified Eagle's,Medium. DME is a ... Eagle [MEM] that contains a ...
... Hollandes is a fixative useful for ... fixation. It is stable and will decalcify ... with Hollande's can be stained successfully with ... the solution stabilizes red blood cell membranes ...
... Gas Chromatograph/Mass Spectrometer, utilizing many of ... Plus, offers high throughput and excellent ... performance-to-cost ratio. Like the GCMS-QP2010 Plus, ... velocity for optimum separation, 20 temperature ...
Biology Products: